ADMA Biologics ADMA Amortization Of License Revenue
Amortization Of License Revenue at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:AmortizationOfLicenseRevenue.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's amortization of license revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's amortization of license revenue?
- ADMA Biologics (ADMA) reported amortization of license revenue of -$36K in Q1 2026.
- How has ADMA Biologics's amortization of license revenue changed year-over-year?
- ADMA Biologics's amortization of license revenue decreased by 0.0% year-over-year, from -$36K to -$36K.
- What is the long-term trend for ADMA Biologics's amortization of license revenue?
- Over 4 years (2021 to 2025), ADMA Biologics's amortization of license revenue has grown at a 0.0% compound annual growth rate (CAGR), from -$143K to -$143K.
- What does amortization of license revenue mean?
- Represents the systematic recognition of deferred revenue related to licensing agreements over the contract period. This metric helps investors track the timing of revenue realization from intellectual property partnerships independent of cash receipts.